Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses.
Mount Sinai researchers have conducted one of the first studies to show the acute effect of obstructive sleep apnea on Alzheimer’s disease biomarkers, and the ability to even measure Alzheimer's disease biomarkers from blood.
A new study from the Icahn School of Medicine at Mount Sinai quantifies the cardiovascular risk posed by exposure to specific environmental factors, showing, for example, that air pollution heightens the risk of heart disease mortality by 17 percent.
Mount Sinai Health System is proud to announce that Kenneth L. Davis, MD, Chief Executive Officer, is among the 2022 class of Modern Healthcare’s 50 Most Influential Clinical Executives award.
Mount Sinai researchers have developed a machine learning algorithm that can determine if an individual has SARS-CoV-2 infections, the virus that causes COVID-19—with a high sensitivity and specificity—from the data collected by wearable devices.
Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR).
Mount Sinai to lead discussions on transgender health, psychedelic therapeutics and long COVID at the 2022 Aspen Ideas: Health and Aspen Ideas Festival.
Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
Mount Sinai researchers have developed a rapid blood assay that measures the magnitude and duration of someone’s immunity to SARS-CoV-2, the virus that causes COVID-19. This test will allow large-scale monitoring of the population’s immunity and the effectiveness of current vaccines to help design revaccination strategies for vulnerable immunosuppressed individuals, according to a study published in Nature Biotechnology in June.
Mount Sinai Brooklyn has earned The Joint Commission’s Gold Seal of Approval ® and the American Stroke Association’s Heart-Check mark for Advanced Primary Stroke Center Certification.
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. Their study was published in the Journal of Experimental & Clinical Cancer Research in June.
Researchers from the Icahn School of Medicine at Mount Sinai have applied a novel stem cell model to map disease risk variants in human neurons, which could help provide insights into the biological mechanisms that underlie neuropsychiatric disorders such as autism and schizophrenia.
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded an initial $16 million from the National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.
Researchers from the Brain Injury Research Center at the Icahn School of Medicine at Mount Sinai, in partnership with the Pennsylvania Department of Corrections (PADOC) and the Brain Injury Assocation of Pennsylvania (BIAPA), have launched a rigorous research study to reduce recidivism, or re-offending, among people with brain injury who are leaving incarceration.
Prolonged delays in breast cancer screening related to the COVID-19 pandemic have led to delayed diagnosis, poor health outcomes, and an increase in disparities. To address this, Mount Sinai Health System has launched “Mammogram May” to empower women to take charge of their breast health by scheduling an annual mammogram.
An advanced radiotherapy technique called radiation segmentectomy may be effective against very early to early-stage hepatocellular carcinoma (HCC), a type of liver cancer that cannot be treated surgically or thermally.
The Icahn School of Medicine at Mount Sinai has launched a new research center devoted to understanding how epigenomics influences the nervous system under both healthy and disease conditions. The Center for Neural Epigenome Engineering aims to dramatically expand Mount Sinai’s ability to conduct research in this field, facilitating new discoveries and the development of long-sought treatments for a variety of neurological and psychiatric disorders. Areas of expansion include chromatin biochemistry, chemical biology, protein engineering, and single-cell “omics.”
The National Institutes of the Health (NIH) has awarded researchers at the Icahn School of Medicine at Mount Sinai a four-year grant to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases. The grant is part of the NIH’s Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which is designed to speed the discovery of new treatments and diagnostics. It will support the Microbiome Technology and Analytic Center Hub (Micro-TEACH), a multidisciplinary team of researchers at Icahn Mount Sinai and NYU Langone Health.
Scientists at the Icahn School of Medicine at Mount Sinai saw for the first time hallmarks of concussions and other head trauma in the brains of deceased headbutting animals—muskoxen and bighorn sheep. The results published in the journal Acta Neuropathologica may contradict the commonly-held belief that ramming animals do not suffer brain injuries and support the notion that studies on animals with brains evolutionarily similar to those of humans may help researchers understand and reduce traumatic brain injuries.
The Mount Sinai Hospital has earned top honors on Newsweek’s list of “America’s Best Maternity Hospitals 2022” for providing high-quality maternity care from pregnancy through birth, as well as postpartum care to ensure the long-term health of both newborns and new mothers.
Marking a major advance in its efforts to achieve equity in the delivery of health care, the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) announced today that its Institute for Health Equity Research (IHER) has received a landmark $20 million gift over five years from Royalty Pharma plc (Nasdaq: RPRX) and certain members of its management team.
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association (AUA) annual meeting in May.
Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai today announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science with medicine. This undertaking will build on a wealth of shared basic research discoveries, explore unique therapeutic innovations in cancer, Alzheimer’s and a myriad of infectious diseases; educate a new generation of biomedical leaders; and develop new technologies and processes that enhance patient outcomes in unprecedented ways. CEPM represents an evolution in the successful partnership between Mount Sinai and RPI, one that has secured over $70 million in shared research funding since 2013 with 90 percent of that provided by the National Institutes of Health.
On May 11 at 3pm, the Icahn School of Medicine at Mount Sinai will grant 127 MD degrees and 43 PhD degrees to the graduating class of 2022 at Carnegie Hall in New York. With a turbulent and memorable medical school journey marked by the COVID-19 pandemic, this year’s class has been severely battle- tested. It is also distinguished as one of Icahn Mount Sinai’s most diverse. Admiral Rachel L. Levine, MD, the first openly transgender federal official to be confirmed by the U.S. Senate, will receive an honorary degree and will deliver the commencement address, while American artist and activist Faith Ringgold will receive an honorary degree.
The cohort study follows women through pregnancy and birth to study if a SARS-CoV-2 infection, the virus that causes COVID-19, is associated with poor pregnancy outcomes.
Researchers share insights about the mechanisms of human embryo and create method to develop transcriptionally similar cells in tissue culture; latest discovery a step closer to finding alternative for bone marrow and other cancer treatments.
CarepathRx, a leader in health system pharmacy and medication management solutions, today announced a comprehensive home infusion pharmacy partnership with Mount Sinai Health System, New York City’s largest academic health system.
Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.
The Emergency Medicine Residents' Association (EMRA) of the American College of Emergency Physicians has honored Brendan G. Carr, MD, MS, Chair of Emergency Medicine at the Icahn School of Medicine of Mount Sinai and Mount Sinai Health System, with the prestigious “2022 Chair of the Year Award.” He is the only department chair in the country to receive this distinction for 2022, recognizing his exceptional leadership.
The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.
Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System in New York, New York, has launched i3 Prism, a technology commercialization fund focused on women and Black, Indigenous and people of color (BIPOC) health care innovators.
Mount Sinai Kravis Children’s Hospital will be the first children’s hospital in Manhattan to use a new, state-of-the art seizure monitoring device that facilitates rapid, point-of-care detection and diagnosis of non-convulsive seizure activity in critically ill children to ensure they receive optimal treatment as quickly as possible.
Mount Sinai Health System has received a top score of 100 and the designation of “LGBTQ+ Healthcare Equality Leader” in the Human Rights Campaign Foundation’s 15th anniversary edition of the Healthcare Equality Index (HEI).
Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge, according to a fast-tracked study in Cancer Cell.
The Milton and Carroll Petrie Department of Urology at Mount Sinai has launched the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit to support prostate health in the Black community.
On Friday, April 1 at 2p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will host a ribbon cutting ceremony in Wagner Houses’ Community Plaza Ground, 451 East 120th Street, to celebrate the launch of the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit.
Mount Sinai researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them.
The Mount Sinai Health System has announced a collaboration with PUSH for Empowered Pregnancy to establish the nation’s first multidisciplinary specialty clinic for women who have experienced stillbirth.